CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Advanced or Metastatic Breast Cancer|
|Funding Request||In combination with an aromatase inhibitor (AI) and a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy|
|Pre Noc Submission||Yes|
|NOC Date||February 7, 2020|
|Manufacturer||Novartis Pharmaceuticals Canada Inc.|
|Sponsor||Novartis Pharmaceuticals Canada Inc.|
|Submission Date||August 26, 2019|
|Submission Deemed Complete||September 10, 2019|
|Stakeholder Input Deadline ‡||September 10, 2019|
|Check-point meeting||November 18, 2019|
|pERC Meeting||March 19, 2020|
|Initial Recommendation Issued||April 2, 2020|
|Feedback Deadline ‡||April 17, 2020|
|pERC Reconsideration Meeting||May 21, 2020|
|Final Recommendation Issued||June 4, 2020|
|Notification to Implement Issued||June 19, 2020|
|Therapeutic Area||HR+, HER2- advanced or metastatic breast cancer|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.